Topical steroidal formulations
View Patent ↗The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.
1. A pharmaceutical composition comprising nanosized particles of a compound of Formula I:
wherein:
R 1 , R 2 and R 7 are hydrogen;
R 3 , R 4 , R 5 and R 6 , are each individually hydrogen or lower alkyl;
X is halogen, hydrogen or lower alkyl;
Z is hydrogen or lower alkyl; and
n is 1 or 2;
wherein at least one of X and Z is not hydrogen; and
suspended in a mixture comprising a lower alkyl alcohol, a surfactant, and optionally, a long chain alcohol.
2. The pharmaceutical composition according to claim 1 wherein said surfactant is a polysorbate or a polyethyleneglycol substituted fatty acid.
3. The pharmaceutical composition according to claim 2 , wherein said polysorbate is selected from the group consisting of polyoxyethylene-20-sorbitan monooleate (Tween 80), polyoxyethylene-20-sorbitan monostearate (Tween 60), polyoxyethylene-20-sorbitan monopalmitate (Tween 40), polyoxyethylene-20-sorbitan monolaurate (Tween 20), polyethyleneglycol stearate, polyethyleneglycol oleate, and mixtures thereof.
4. The pharmaceutical composition according to claim 3 wherein said polysorbate is polyoxyethylene-20-sorbitan monooleate (Tween 80), and wherein said pharmaceutical composition comprises a lower alkyl alcohol in the range of from about 30 to about 90% (v/v), polyoxyethylene-20-sorbitan monooleate (Tween 80) in the range of from about 0.01% to about 3.5% and water in the range of from about 0% to about 60%.
5. The pharmaceutical composition of according to claim 1 , wherein said long chain alcohol corresponds to the formula CH 3 (CH 2 ) n —OH, wherein n is an integer in the range of 9-24.
6. The pharmaceutical composition according to claim 5 , wherein said long chain alcohol is selected from the group consisting of decyl alcohol, cetyl alcohol, stearyl alcohol, lauryl alcohol, myristyl alcohol, oleyl alcohol and mixtures thereof.
7. The pharmaceutical composition according to claim 1 , further comprising water.
8. The pharmaceutical composition according to claim 1 , wherein the compound of Formula I is 16α-methyl-5-androsten-17-one or 3β-methyl-16α-methyl-5-androsten-17-one.
9. A transdermal delivery system comprising the pharmaceutical composition of claim 1 .
10. A topical formulation comprising the pharmaceutical composition of claim 1 .
11. A method for the treatment of obesity, diabetes, arthritis or metabolic syndrome in a patient in need thereof, which comprises administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 1 .
12. The method according to claim 11 , wherein said treatment is for diabetes.
13. The method according to claim 11 , wherein the treatment is for obesity.
14. The method according to claim 11 , wherein the treatment is for rheumatoid arthritis or osteoarthritis.
15. The pharmaceutical composition according to claim 1 in the form of a gel, said gel further comprising water, a thickening agent, and optionally a base.
16. The gel according to claim 15 wherein the surfactant is a polysorbate.
17. The gel according to claim 15 , wherein said polysorbate is selected from the group consisting of polyoxyethylene-20-sorbitan monooleate (Tween 80), polyoxyethylene-20-sorbitan monostearate (Tween 60), polyoxyethylene-20-sorbitan monopalmitate (Tween 40), polyoxyethylene-20-sorbitan monolaurate (Tween 20), and mixtures thereof.
18. The gel according to claim 15 which comprises from about 30 to about 90% (v/v) lower alcohol, and from about 0.01 to about 5% (v/v) surfactant.
19. The gel according to claim 15 , wherein said lower alkyl alcohol is selected from the group consisting of ethanol, methanol, butanol, pentanol, isopropanol and n-propanol.
20. The gel according to claim 15 , wherein said base is selected from the group consisting of triethanolamine, diethanolamine and triethylamine.
21. The gel according to claim 15 , wherein the compound of Formula I is 16α-methyl-5-androsten-17-one or 3β-methyl-16α-methyl-5-androsten-17-one.
22. A transdermal delivery system comprising the gel of claim 15 .
23. A topical formulation comprising the gel of claim 15 .
24. A method for the treatment of obesity, arthritis, diabetes or metabolic syndrome in a patient in need thereof, which comprises administering to said patient a therapeutically effective amount of a composition comprising the gel according to claim 15 .
25. The method according to claim 24 , wherein said treatment is for diabetes.
26. The method according to claim 24 , wherein the treatment is for obesity.
27. The method according to claim 24 , wherein the treatment is for rheumatoid arthritis or osteoarthritis.
28. A method of preparing a gel according to claim 15 comprising the steps of mixing a lower alkyl alcohol, a surfactant, water, nanosized particles of a compound of Formula I, to form a mixture; adding to said mixture and mixing therewith a thickening agent; and incubating said ingredients until gel formation.
29. The method according to claim 28 , wherein said lower alkyl alcohol is selected from the group consisting of ethanol, methanol, butanol, pentanol, isopropanol and n-propanol.
30. The method according to claim 28 wherein the surfactant is a polysorbate.
31. The method according to claim 30 , wherein said polysorbate is selected from the group consisting of polyoxyethylene-20-sorbitan monooleate (Tween 80), polyoxyethylene-20-sorbitan monostearate (Tween 60), polyoxyethylene-20-sorbitan monopalmitate (Tween 40), polyoxyethylene-20-sorbitan monolaurate (Tween 20), and mixtures thereof.
32. The method according to claim 28 , wherein said thickening agent is a cross-linked acrylic acid polymer.
33. The pharmaceutical composition according to claim 1 , wherein the compound of Formula I is 3β-methyl-16α-methyl-5-androsten-17-one.
34. The gel according to claim 15 , wherein the compound of Formula I is 3β-methyl-16α-methyl-5-androsten-17-one.